Platinum anticancer complexes beyond cisplatin
The 16th International Symposium on Applied Bioinorganic Chemistry (ISABC) convened in Ioannina, Greece, in June 2023 under the organisation of the University of Ioannina. The meeting surveyed applied bioinorganic chemistry and placed platinum anticancer complexes with non-classical mechanisms within a broad scientific setting.
These complexes are often introduced through cisplatin, oxaliplatin and carboplatin, but their therapeutic behaviour depends on more than DNA adducts. Protein binding, thiol chemistry, redox balance, membrane effects and cellular stress can all shape potency, selectivity and resistance, giving researchers alternative routes to attack difficult tumours.
For Australian scientists and clinicians, this focus was especially timely. Cancer research groups around Melbourne, Sydney, Brisbane, Adelaide and Perth were well placed to contribute mechanistic, medicinal-chemistry and translational studies, while the symposium’s travel awards, poster prizes and scholarships supported early-career participation and cross-border collaboration.
Why non-classical mechanisms matter
Cisplatin remains a benchmark because aquation and DNA binding can produce lethal transcription stress. Yet a compound’s fate in blood is not simple: chloride concentration, albumin, cellular uptake and efflux alter the species that reach a tumour. Cellular shielding through glutathione and other nucleophiles can further change the dose required for a response.
Non-classical activity may arise when a platinum complex perturbs mitochondrial respiration, triggers reactive oxygen species, disrupts proteostasis or activates autophagic and immune responses. Some compounds may enter cells without forming the canonical DNA-lesion profile. These pathways offer plausible explanations for activity against resistant disease, provided the claims survive careful mechanistic testing.
A rigorous programme therefore needs more than a viability curve. Concentration, time and exposure format must match what patients receive, while comparator platinum drugs and non-platinum controls help separate generic toxicity from metal-specific effects. Spectroscopy, mass spectrometry and imaging can connect chemical speciation with the cell state that follows treatment.
Designing platinum drugs for resistant tumours
Design choices now span ligand architecture, charge, lipophilicity, carrier systems and selective targeting ligands. These features influence pharmacokinetics, tumour penetration and the balance between nuclear and off-target interactions. A promising candidate needs a defensible structure–activity relationship, rather than simply greater cytotoxicity in one screening line.
The wider ISABC programme encouraged this kind of cross-fertilisation between coordination chemistry and disease biology. A related feature of the meeting’s insights was an examination of copper links in neurodegeneration, illustrating how metal complexes can be evaluated against complex disease pathways instead of a single molecular target.
For platinum research, useful readouts might combine cell-death markers with respiration, proteomic changes, DNA damage and macrophage responses. Patient-derived models and organoids can then test whether a mechanistic advantage survives tumour architecture and stromal signals. Multi-omics and metallomics are valuable here, provided sample-preparation controls preserve the metal species being investigated.
Translation within Australia’s health system
Australian translation operates through a mixed landscape of public hospitals, private providers, universities and specialist oncology networks. Public cancer treatment is delivered through Medicare-funded services, while cytotoxic medicines are commonly managed through hospital formularies and multidisciplinary tumour boards instead of ordinary retail purchasing. Platinum agents are therefore handled within specialist oncology pathways, making formulation, preparation and administration central to any clinical translation plan.
The Therapeutic Goods Administration regulates therapeutic goods in Australia, and interventional studies require relevant ethics and site approval. Teams should distinguish an analytical result from a claim of clinical efficacy, then plan regulatory engagement early. The same discipline applies to repurposing compounds, where manufacturing consistency and a reproducible formulation remain central.
Geography adds another practical layer. Researchers in Perth or Brisbane cannot assume that laboratory material, collaborators or clinical samples move as quickly as those in a compact capital-city cluster, and Australia spans several time zones. June is winter in Australia but part of the warm season in Ioannina, so delegates from Perth, Adelaide, Melbourne, Sydney and Brisbane should plan time-zone differences, sample logistics and equipment transfer carefully before travel.
Local communication has its own rhythm too: an “arvo” catch-up may be casual and direct, with “fair dinkum” used when an argument is considered genuine. Written reports still require precision, but the friendly style of conference discussion can make it easier to uncover practical obstacles and identify collaborators.
Priorities for an Australian research network
Collaboration across these systems will be strongest when chemistry, biology and clinical questions are designed together. The symposium’s young scientist travel awards, poster prizes and scholarships can help build that pipeline, while clear application requirements allow applicants to prepare proposals before contacting the official secretariat.
For an Australian delegation, the following priorities are especially useful:
- Pair each platinum candidate with defined chemical controls, including the free ligand, an inactive analogue and a matched non-platinum complex.
- Test stability in biologically realistic media and report the actual exposure window instead of only the nominal dose.
- Use resistant models with mechanistic endpoints that distinguish apoptosis, ferroptosis, autophagy and non-apoptotic cell death.
- Compare results across dosing schedules and tumour, normal or stromal models before making selectivity claims.
- Engage pathology, pharmacology and data-quality teams early, using Australian spelling and transparent reporting for international review.
- Budget for long-haul travel, time-zone coordination and sample transfer, while building remote presentation options into the collaboration plan.
These priorities protect the interpretive value of mechanistic findings, make cross-laboratory datasets easier to compare and give early-career researchers a clearer route from a poster result to a funded collaboration. Supporting material and further links for continued work can also be explored through the PT-16 online resources.
Take part in the symposium exchange
ISABC 2023 connected coordination chemistry with tumour biology, provided a platform for young investigators and demonstrated how rigorous mechanistic work can address resistance. The organising University of Ioannina and the wider meeting community created a useful bridge between laboratory design and patient-centred translation.
Use the official symposium information to review participation routes, awards and poster opportunities. For registration, accommodation or abstract-related enquiries, contact Zita Congress & Event Management, the official symposium secretariat. Researchers should arrive with a focused mechanistic question, share reproducible data and invite Australian and international collaborators to test it together.